How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) issued its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.05. The biotechnology company had revenue of $152.05 million for the quarter, compared to analyst estimates of $132.78 million. Cambrex had a trailing twelve-month return on equity of 5.38% and a net margin of 5.96%. The firm's revenue for the quarter was up 13.0% on a year-over-year basis. During the same period last year, the company earned $0.76 earnings per share.

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Illumina (ILMN) , AbbVie (ABBV) , NVIDIA (NVDA) , CVS Health (CVS) , Gilead Sciences (GILD) , Intel (INTC) , Walt Disney (DIS) , Juno Therapeutics (JUNO) and Under Armour (UAA) .

NYSE:CBM

Cambrex (CBM) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free CBM Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $59.99
▼
$59.99
50-Day Range: $59.99
▼
$59.99
52-Week Range: $33.80
▼
$60.29

Volume: N/A
Average Volume: 218,726 shs
Market Capitalization: $2.02 billion

P/E Ratio: 21.66
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Cambrex alerts:

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Cambrex Stock (NYSE:CBM)

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

CBM Stock News Headlines

March 27, 2024 | tmcnet.com

One Equity Partners Invests in Italian Agricultural Tractor Attachment Manufacturer CBM

March 19, 2024 | morningstar.com

China CBM Group Co Ltd 08270

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

November 2, 2023 | finance.yahoo.com

Cambrex Announces Sale of Drug Product Business Unit

October 29, 2023 | investing.com

CBM_old Historical Data

October 24, 2023 | finance.yahoo.com

Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development

October 18, 2023 | stockhouse.com

SK pharmteco to showcase its extensive APIs and CGT capabilities in CPHI 2023

September 21, 2023 | businesswire.com

SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in Center for Breakthrough Medicines

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

September 7, 2023 | finance.yahoo.com

Cleantech Building Materials: Result of General Meeting

August 29, 2023 | markets.businessinsider.com

DIVERGENT Energy Services Announces the Release of 2023 Second Quarter Results

August 14, 2023 | finance.yahoo.com

Cleantech Building Materials: Notice of General Meeting

May 31, 2023 | markets.businessinsider.com

Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement

May 30, 2023 | juniorminingnetwork.com

Collective Mining Drills 162.20 Metres at 3.90 g/t Gold Equivalent From Surface at the...

January 18, 2023 | prnewswire.com

Cambrex fait l'acquisition de Snapdragon Chemistry, un leader dans les services de développement d'IPA à flux continu

December 24, 2022 | msn.com

Repair works at LRT, MRT, Monorail stations to be completed by February

October 14, 2022 | businesswire.com

Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2028 - ResearchAndMarkets.com - Business Wire

October 9, 2022 | benzinga.com

With 5.0% CAGR, Small Molecule API Market Size Worth US$ 300.2 Billion by 2030 | Research for Developing - Benzinga

October 5, 2022 | markets.businessinsider.com

Cambrex Announces Stability Storage Expansions in Ireland and Belgium

October 4, 2022 | prnewswire.com

Cambrex Announces Stability Storage Expansions in Ireland and Belgium - PR Newswire

September 28, 2022 | streetinsider.com

Medicx Health Appoints Theresa Greco as President and Stacey Levas as Senior Vice President of Marketing - StreetInsider.com

September 27, 2022 | prnewswire.com

Investigational New Drug CDMO Market worth $7.47 billion by 2030 - Exclusive Report by InsightAce Analytic - PR Newswire

September 20, 2022 | finance.yahoo.com

Blockchain Moon Acquisition Corp. appoints John P. Hopkins and Carl J. Johnson as new Independent Directors - Yahoo Finance

September 19, 2022 | msn.com

ONGC wants government to scrap windfall tax on domestically produced crude oil

September 19, 2022 | msn.com

ONGC wants govt to scrap windfall tax, USD 10 gas price

September 16, 2022 | businesswire.com

Kimball Electronics, Inc. Announces Appointment of Additional Director - Business Wire

September 2, 2022 | news.yahoo.com

Cambrex finishes first phase of expansion - Yahoo News

See More Headlines

Receive CBM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cambrex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/02/2018
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Life Sciences Tools & Services
Current Symbol: NYSE:CBM
CUSIP: 13201110
CIK: 820081
Web: www.cambrex.com
Phone: 201-804-3000
Fax: N/A
Employees: 1,732
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $2.77
Trailing P/E Ratio: 21.66
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $92.41 million
Net Margins: 5.96%
Pretax Margin: N/A
Return on Equity: 5.38%
Return on Assets: 2.50%

Debt

Debt-to-Equity Ratio: 0.76
Current Ratio: 2.37
Quick Ratio: 1.70

Sales & Book Value

Annual Sales: $532.09 million
Price / Sales: 3.80
Cash Flow: $3.91 per share
Price / Cash Flow: 15.36
Book Value: $19.48 per share
Price / Book: 3.08

Miscellaneous

Outstanding Shares: 33,720,000
Free Float: N/A
Market Cap: $2.02 billion
Optionable: Optionable
Beta: 2.14

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Steven M. Klosk (Age 62)
Pres, CEO & Director
Mr. Gregory P. Sargen (Age 53)
Exec. VP of Corp. Devel. & Strategy and CFO
Mr. Shawn P. Cavanagh (Age 53)
Exec. VP & COO
Ms. Samantha M. Hanley (Age 41)
VP, Gen. Counsel & Corp. Sec.
Mr. James G. Farrell (Age 52)
VP & Corp. Controller

Key Competitors

View All Competitors

CBM Stock Analysis - Frequently Asked Questions

How were Cambrex's earnings last quarter?: Cambrex Co. (NYSE:CBM) issued its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.05. The biotechnology company had revenue of $152.05 million for the quarter, compared to analyst estimates of $132.78 million. Cambrex had a trailing twelve-month return on equity of 5.38% and a net margin of 5.96%. The firm's revenue for the quarter was up 13.0% on a year-over-year basis. During the same period last year, the company earned $0.76 earnings per share.
What other stocks do shareholders of Cambrex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Illumina (ILMN), AbbVie (ABBV), NVIDIA (NVDA), CVS Health (CVS), Gilead Sciences (GILD), Intel (INTC), Walt Disney (DIS), Juno Therapeutics (JUNO) and Under Armour (UAA).

This page (NYSE:CBM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cambrex (CBM) Stock Price, News & Analysis

About Cambrex Stock (NYSE:CBM)

CBM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CBM Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info